“BioSpace (DHX) is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States. Once BioSpace sorted the companies into that group, they were then weighted by a number of different categories and ranked in a cumulative fashion based on the points awarded for each category. These categories are: Finance, Collaborations, Pipeline, Sales and Editorial (view methodology).
The NextGen Bio Class of 2016 is a stellar group of companies that are already making an enormous impact on the industry now and in the future. Congratulations!
California led the way in the NextGen Bio “Class of 2016” with half of the companies in the Top 20, followed by Massachusetts with five, and one company each in New Jersey, Texas, New York, Washington and North Carolina.”
Bay Area Companies on List:
1. Corvus Pharma
Location: Burlingame, Calif.
• Corvus Pharma is a clinical-stage biopharmaceutical company focused on immuno-oncology. The company currently has a Checkpoint inhibitor in Phase I clinical trials, which is expected to move into Phase IB in early 2016. It has another Checkpoint inhibitor in preclinical development as well as a T cell reprograming drug in preclinical development.
• In December 2014, Corvus closed on a $33.5 million Series A funding round led by OrbiMed Advisors.
• On September 29, 2015, the company closed on a $75 million Series B financing, led by Rock Springs Capital Management, and included Fidelity Management and Research Company, Blackrock, funds and accounts managed by T. Rowe Price, Jennison Associates, Roche Venture Fund, Cormorant Asset Management, Sphera Funds Management,venBio Select and Cowen Private Investments. Also participating were founding investors Orbimed, Novo Ventures andAdams Street Partners. Cowen and Company acted as advisors.
9. True North Therapeutics
Location: South San Francisco, Calif.
• True North is working to develop novel therapies that selectively inhibit the complement system to treat diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, selectively targets the classical complement pathway, enabling inhibition of downstream phagocytosis, inflammation and cell lysis. True North is advancing a pipeline of novel monoclonal antibodies. for complement-mediated rare diseases in the hematologic, kidney transplant, and skin therapeutic areas.
• In April 2014, the company closed on a Series B financing round worth $35 million.
• In June 2014, it closed on a Series A round worth $22 million.
• TrueNorth is a spinout of iPierian
Location: Emeryville, Calif.
• Zymergen focuses on genetically engineering microbes for industrial fermentation.
• It raised $44 million in 2015 and $2 million in seed funding in 2013. The Series A was led by Data Collective, joined by AME Cloud Ventures, Draper Fisher Jurvetson, HVF, Innovation Endeavors, Obvious Ventures, True Ventures and Two Sigma Ventures.
• Zymergen’s approach involves automation and bioinformatics approaches, in what has been described as a combination of Darwinian selection of genetically engineered microbes combined with machine learning, analysis and automation.